70 chief strategy officers to know | 2024
Becker’s is proud to recognize 70 outstanding chief strategy officers leading hospitals and health systems in 2024.
Related Articles
High-fiber diet may slow progression of precursor conditions to multiple myeloma
SAN DIEGO — A high-fiber plant-based diet may delay progression of certain precursor conditions to multiple myeloma, according to study results presented at ASH Annual…
Colorectal cancer harboring EGFR kinase domain duplication response to EGFR tyrosine kinase inhibitors
This case report provides evidence of clinical benefit from EGFR tyrosine kinase inhibitors in colorectal cancer harboring EGFR kinase domain duplication.
CAR-T Meeting 2025 | VJHemOnc
Jointly organized by the EHA and EBMT, the 7th European CAR T-cell Meeting is taking place on February 6-8, 2025, in Strasbourg, France, and online,…
Home
Advanced Cancer Therapies serves as a comprehensive forum to promote research, development and application of advanced cancer therapies. This event promotes education and the exchange…
Intricacies of EGFR-Mutated NSCLC Care From the Patient Perspective
Alexander Spira, MD, and Julia Lazo, RN, spoke with Melinda Reubens, who was diagnosed with EGFR-mutant NSCLC, and her husband Justin.
inMIND trial: Tafasitamab plus lenalidomide and rituximab for R/R FL
During the 66th ASH Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak to Stefano Luminari about the latest updates from the inMIND…
Menin inhibitors in the treatment of acute myeloid leukemia
In this Blood Spotlight, Huls et al highlight why small molecule inhibitors of menin are creating excitement in the acute myeloid leukemia (AML) field with
Nivolumab Plus Chemo Shows Long-Term OS Benefit in Chinese Patients With Advanced Gastric, GEJ, or Esophageal Cancer
Nivolumab plus chemotherapy demonstrated long-term survival benefits in advanced gastric, GEJ, or esophageal cancer in China.
Biomarker-Directed Radiotherapy in Breast Cancer
This narrative review explores the potential of biomarker-directed personalized radiotherapy approaches.
